Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use

A technology of calcium ion antagonist and telmisartan, applied in the field of pharmaceutical compounds, can solve problems such as low treatment rate and control rate, and achieve the effects of less adverse reactions, over-activation of the sympathetic system, and reduction of drug dosage.

Active Publication Date: 2007-02-07
SUZHOU DAWNRAYS PHARM CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From the above statistics, it can be seen that the prevalence of hypertension in my country continues to increase, but the treatment rate and control rate are low, forming a huge contrast

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use
  • Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] 1. Materials and methods

[0030] 1.1 Case selection: Mild to moderate hypertensive patients aged 18 to 65 in outpatient and inpatient, sitting diastolic blood pressure 95 to 115 mmHg, systolic blood pressure <200 mmHg, not accompanied by serious target organ damage, male or female. The diagnosis of hypertension was in line with WHO criteria. The following conditions are excluded: severe liver or kidney dysfunction, severe alcohol and tobacco addiction, pregnant women, breastfeeding women, and those who have been ineffective or intolerable to the above-mentioned drug treatments in the past.

[0031] 1.2 Test method: All 120 patients stopped using other drugs that affect blood pressure for more than 5 half-lives before treatment, asked about medical history and various examinations in detail, except for secondary hypertension. They were randomly divided into 4 groups: ① low-low dose combination group: amlodipine (Aml, Pfizer Pharmaceutical Co., Ltd.) 2.5 mg / telmisartan...

Embodiment 2

[0044] 1. Materials and methods

[0045] 1.1 Case selection:

[0046] Mild to moderate hypertensive patients aged 18 to 65 in outpatient or hospital, sitting diastolic blood pressure 95 to 115mmHg, systolic blood pressure <200mmHg, not accompanied by serious target organ damage, male or female. The diagnosis of hypertension was in line with WHO criteria. The following conditions are excluded: severe liver or kidney dysfunction, severe alcohol and tobacco addiction, pregnant women, breastfeeding women, and those who have been ineffective or intolerable to the above-mentioned drug treatments in the past.

[0047] 1.2 Test method: All 150 patients stopped using other drugs that affect blood pressure for more than 5 half-lives before treatment, asked about medical history and various examinations in detail, except for secondary hypertension. Randomly divided into 3 groups: ① low-low dose combination group: levamlodipine (Lam, Tianfeng Pharmaceutical Co., Ltd.) 1.25 mg / telmisart...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use. The inventive compound preparation is composed of following components by weight portion: 10-160 portion of timishatan, 0.5-50 protion of calcium antagonist. The calcium antagonist expands blood vessel to induce reflex sympathetic nerve excitement and the timishatan antagonizes neurohormone activity which is able to release from the sympathicus over-activation in the CCB blood pressure reduction, reduce the adverse effect induced by CCB treatment, provide all-around protection of the target organ such as heart, brain and kidney. The association of two acts synergistic effect to reduce blood pressure.

Description

technical field [0001] The invention relates to the field of pharmaceutical compounds, in particular to a compound antihypertensive preparation. Background technique [0002] Hypertension is the most common cardiovascular disease and a major public health problem worldwide. In 1991, my country conducted a sample survey of 940,000 people over the age of 15. Statistics show that the prevalence of hypertension in my country has reached 11.26%, which is 25% higher than that in the 10 years from 1979 to 1990. There are more than 130 million hypertensive patients in my country. . Moreover, this upward momentum continues. Statistics also show that the treatment rate of hypertension is 17.4% in urban areas and 5.4% in rural areas; the control rate (systolic blood pressure<140mmHg and diastolic blood pressure<90mmHg after treatment) is only 2.9%. From the above statistics, it can be seen that the prevalence of hypertension in my country is constantly increasing, but the treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/4422A61P9/12
Inventor 林曙光余细勇郑猛
Owner SUZHOU DAWNRAYS PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com